BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia
| العنوان: | BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia |
|---|---|
| المؤلفون: | Catherine Roche-Lestienne, Sylvie Galiègue-Zouitina, Eileen M Boyle, Sabine Tricot, Stéphanie Poulain, Aline Renneville, Guillemette Marot, Nicolas Poret, Bruno Quesnel, Christophe Roumier, Claude Preudhomme, Guillemette Fouquet, Xavier Leleu, Natacha Broucqsault, Olivier Nibourel, Elisabeth Bertrand, Charles Herbaux, Franck Morschhauser, Valérie Soenen |
| المساهمون: | CHU Lille, Inserm, Université de Lille, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS], METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), MOdel for Data Analysis and Learning (MODAL), Laboratoire Paul Painlevé (LPP), Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Sciences et Technologies-Inria Lille - Nord Europe, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-École polytechnique universitaire de Lille (Polytech Lille), Service d'Hématologie Cellulaire [Lille], CH Valenciennes, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Laboratoire Paul Painlevé - UMR 8524 (LPP), Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Université de Lille, Sciences et Technologies-Inria Lille - Nord Europe, Marot, Guillemette |
| المصدر: | Oncotarget Oncotarget, 2016 Oncotarget, Impact journals, 2016 |
| بيانات النشر: | Impact journals, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Candidate gene, medicine.medical_specialty, Pathology, Tumor suppressor gene, [SDV]Life Sciences [q-bio], BACH2, Asymptomatic, 03 medical and health sciences, [MATH.MATH-ST]Mathematics [math]/Statistics [math.ST], Progression, Waldenström macroglobulinemia, Indolent, Physiopathology, Internal medicine, indolent, medicine, Clonogenic assay, [MATH.MATH-ST] Mathematics [math]/Statistics [math.ST], business.industry, Waldenstrom macroglobulinemia, Macroglobulinemia, Gene signature, medicine.disease, Pathophysiology, 3. Good health, [SDV] Life Sciences [q-bio], 030104 developmental biology, progression, medicine.symptom, Clinical Research Paper, physiopathology, business |
| الوصف: | International audience; Approximately 30% of the patients who fulfil the criteria of Waldenström's macroglobulinemia (WM) are diagnosed while asymptomatic (indolent), and will not require immediate therapy. Conversely, patients with a disease-related event will be considered for therapy. The physiopathology of these 2 groups remains unclear, and the mechanisms of progression from indolent to symptomatic WM have yet to be fully understood. Seventeen patients diagnosed with WM were included in this study, 8 asymptomatic WM (A-WM) and 9 symptomatic WM (S-WM). A differential analysis was performed on a first series of 11 patients and identified 48 genes whose expression separated samples from A-to S-WM. This gene signature was then confirmed on a second independent validation set of 6 WM. Within this expression profile, BACH2, a B-cell transcription factor known to be a tumor suppressor gene, was found to be over-expressed in A-MW relatively to S-MW. We specifically over-expressed BACH2 in a WM-related cell line and observed a significant reduction of the clonogenic activity. To the best of our knowledge, we report for the first time a specific gene expression signature that differentiates A-WM and S-WM. Within this expression profile, BACH2 was identified as a candidate gene that may help to understand better the behavior of tumor cells in indolent WM. |
| وصف الملف: | application/pdf; application/rdf+xml; charset=utf-8 |
| اللغة: | English |
| تدمد: | 1949-2553 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de2961182e0b3dd589aafe6e7eb6800Test http://hdl.handle.net/20.500.12210/29230Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1de2961182e0b3dd589aafe6e7eb6800 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19492553 |
|---|